{"id":63568,"date":"2026-04-20T20:31:26","date_gmt":"2026-04-20T12:31:26","guid":{"rendered":"https:\/\/flcube.com\/?p=63568"},"modified":"2026-04-20T20:31:27","modified_gmt":"2026-04-20T12:31:27","slug":"hansoh-pharmaceutical-presents-promising-phase-i-data-for-b7-h3-adc-risvutatug-rezetecan-combined-with-adebrelimab-at-aacr-2026-47-1-orr-and-14-0-month-pfs-in-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63568","title":{"rendered":"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors"},"content":{"rendered":"\n<p><strong>Hansoh Pharmaceutical Group Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) unveiled <strong>Phase I clinical trial results<\/strong> for <strong>risvutatug rezetecan<\/strong> (HS-20093\/GSK5764227), a <strong>B7-H3-targeting antibody-drug conjugate<\/strong> (ADC), in combination with <strong>adebrelimab<\/strong>, a fully human anti-PD-L1 monoclonal antibody, at the <strong>American Association for Cancer Research Annual Meeting<\/strong> (AACR 2026) in San Diego. The open-label, multi-center study demonstrated <strong>encouraging anti-tumor activity<\/strong> with a <strong>47.1% confirmed objective response rate<\/strong> (ORR) and <strong>14.0-month median progression-free survival<\/strong> (PFS), validating Hansoh&#8217;s strategic partnership with GSK following their exclusive global licensing agreement in December 2023.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results-summary\">Clinical Trial Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Efficacy Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Objective Response Rate<\/strong> (ORR)<\/td><td><strong>47.1%<\/strong> (confirmed)<\/td><\/tr><tr><td><strong>Disease Control Rate<\/strong> (DCR)<\/td><td><strong>94.1%<\/strong><\/td><\/tr><tr><td><strong>Median Duration of Response<\/strong> (DoR)<\/td><td><strong>12.6 months<\/strong><\/td><\/tr><tr><td><strong>Median Progression-Free Survival<\/strong> (PFS)<\/td><td><strong>14.0 months<\/strong> (32.4% event rate)<\/td><\/tr><tr><td><strong>Overall Survival<\/strong> (OS)<\/td><td>Immature data<\/td><\/tr><tr><td><strong>Study Design<\/strong><\/td><td>Open-label, multi-center Phase I<\/td><\/tr><tr><td><strong>Presentation Venue<\/strong><\/td><td>AACR Annual Meeting 2026 (April 17\u201322, San Diego)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risvutatug Rezetecan:<\/strong> B7-H3-targeting antibody-drug conjugate (ADC) under investigation for multiple solid tumors<\/li>\n\n\n\n<li><strong>Adebrelimab:<\/strong> Fully human anti-PD-L1 IgG4 monoclonal antibody, approved in China for first-line extensive-stage small cell lung cancer<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Dual mechanism targeting tumor cells (B7-H3 ADC) while enhancing immune response (PD-L1 inhibition)<\/li>\n\n\n\n<li><strong>B7-H3 Target:<\/strong> Expressed on various solid tumors with limited expression in normal tissues, providing favorable therapeutic window<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-profile-manageable-toxicity\">Safety Profile \u2013 Manageable Toxicity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Safety Parameter<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Treatment-Related Deaths<\/strong><\/td><td>None reported<\/td><\/tr><tr><td><strong>Grade \u22653 Adverse Events<\/strong><\/td><td>Primarily hematological: decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, and anemia<\/td><\/tr><tr><td><strong>Discontinuation Rate<\/strong><\/td><td>Not specified, but manageable overall profile<\/td><\/tr><tr><td><strong>Safety Conclusion<\/strong><\/td><td>Combination demonstrated manageable safety profile consistent with expected profiles of individual agents<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-context\">Strategic Partnership Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partnership Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensing Agreement<\/strong><\/td><td>December 2023 between Hansoh and GSK<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Exclusive global license to GSK (excluding mainland China, Hong Kong, Macau, and Taiwan)<\/td><\/tr><tr><td><strong>Development Rights<\/strong><\/td><td>GSK responsible for Phase I and III trials outside Greater China<\/td><\/tr><tr><td><strong>Commercial Rights<\/strong><\/td><td>GSK holds global commercialization rights excluding Greater China<\/td><\/tr><tr><td><strong>Hansoh Retention<\/strong><\/td><td>Full rights in Greater China market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications-amp-competitive-positioning\">Market Implications &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>B7-H3 ADC Market:<\/strong> Emerging target class with multiple competitors in development across major pharmaceutical companies<\/li>\n\n\n\n<li><strong>Combination Therapy Trend:<\/strong> PD-(L)1 combinations with ADCs represent next-generation approach to enhance efficacy beyond monotherapy<\/li>\n\n\n\n<li><strong>Solid Tumor Opportunity:<\/strong> Broad applicability across multiple B7-H3-expressing solid tumors including lung, breast, prostate, and ovarian cancers<\/li>\n\n\n\n<li><strong>China Market Advantage:<\/strong> Hansoh retains full commercial rights in Greater China, the world&#8217;s second-largest pharmaceutical market<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap-amp-next-steps\">Development Roadmap &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase II\/III Planning:<\/strong> Data supports advancement to later-stage trials based on robust efficacy signals<\/li>\n\n\n\n<li><strong>Tumor Type Expansion:<\/strong> Potential expansion into specific B7-H3-high tumor populations for enhanced efficacy<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Parallel development pathways in Greater China (Hansoh-led) and global markets (GSK-led)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential. Actual results may differ due to risks including later-stage trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,35,16,17,363,1182],"class_list":["post-63568","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-adc-xdc","tag-cancer","tag-clinical-trial-results","tag-hansoh-pharmaceutical","tag-hkg-3692"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug rezetecan (HS-20093\/GSK5764227), a B7-H3-targeting antibody-drug conjugate (ADC), in combination with adebrelimab, a fully human anti-PD-L1 monoclonal antibody, at the American Association for Cancer Research Annual Meeting (AACR 2026) in San Diego. The open-label, multi-center study demonstrated encouraging anti-tumor activity with a 47.1% confirmed objective response rate (ORR) and 14.0-month median progression-free survival (PFS), validating Hansoh&#039;s strategic partnership with GSK following their exclusive global licensing agreement in December 2023.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63568\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug rezetecan (HS-20093\/GSK5764227), a B7-H3-targeting antibody-drug conjugate (ADC), in combination with adebrelimab, a fully human anti-PD-L1 monoclonal antibody, at the American Association for Cancer Research Annual Meeting (AACR 2026) in San Diego. The open-label, multi-center study demonstrated encouraging anti-tumor activity with a 47.1% confirmed objective response rate (ORR) and 14.0-month median progression-free survival (PFS), validating Hansoh&#039;s strategic partnership with GSK following their exclusive global licensing agreement in December 2023.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63568\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-20T12:31:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-20T12:31:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63568#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63568\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors\",\"datePublished\":\"2026-04-20T12:31:26+00:00\",\"dateModified\":\"2026-04-20T12:31:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63568\"},\"wordCount\":494,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial results\",\"Hansoh Pharmaceutical\",\"HKG: 3692\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63568#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63568\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63568\",\"name\":\"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-20T12:31:26+00:00\",\"dateModified\":\"2026-04-20T12:31:27+00:00\",\"description\":\"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug rezetecan (HS-20093\\\/GSK5764227), a B7-H3-targeting antibody-drug conjugate (ADC), in combination with adebrelimab, a fully human anti-PD-L1 monoclonal antibody, at the American Association for Cancer Research Annual Meeting (AACR 2026) in San Diego. The open-label, multi-center study demonstrated encouraging anti-tumor activity with a 47.1% confirmed objective response rate (ORR) and 14.0-month median progression-free survival (PFS), validating Hansoh's strategic partnership with GSK following their exclusive global licensing agreement in December 2023.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63568#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63568\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63568#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug rezetecan (HS-20093\/GSK5764227), a B7-H3-targeting antibody-drug conjugate (ADC), in combination with adebrelimab, a fully human anti-PD-L1 monoclonal antibody, at the American Association for Cancer Research Annual Meeting (AACR 2026) in San Diego. The open-label, multi-center study demonstrated encouraging anti-tumor activity with a 47.1% confirmed objective response rate (ORR) and 14.0-month median progression-free survival (PFS), validating Hansoh's strategic partnership with GSK following their exclusive global licensing agreement in December 2023.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63568","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors","og_description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug rezetecan (HS-20093\/GSK5764227), a B7-H3-targeting antibody-drug conjugate (ADC), in combination with adebrelimab, a fully human anti-PD-L1 monoclonal antibody, at the American Association for Cancer Research Annual Meeting (AACR 2026) in San Diego. The open-label, multi-center study demonstrated encouraging anti-tumor activity with a 47.1% confirmed objective response rate (ORR) and 14.0-month median progression-free survival (PFS), validating Hansoh's strategic partnership with GSK following their exclusive global licensing agreement in December 2023.","og_url":"https:\/\/flcube.com\/?p=63568","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-20T12:31:26+00:00","article_modified_time":"2026-04-20T12:31:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63568#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63568"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors","datePublished":"2026-04-20T12:31:26+00:00","dateModified":"2026-04-20T12:31:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63568"},"wordCount":494,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","ADC \/ XDC","Cancer","Clinical trial results","Hansoh Pharmaceutical","HKG: 3692"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63568#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63568","url":"https:\/\/flcube.com\/?p=63568","name":"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-20T12:31:26+00:00","dateModified":"2026-04-20T12:31:27+00:00","description":"Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) unveiled Phase I clinical trial results for risvutatug rezetecan (HS-20093\/GSK5764227), a B7-H3-targeting antibody-drug conjugate (ADC), in combination with adebrelimab, a fully human anti-PD-L1 monoclonal antibody, at the American Association for Cancer Research Annual Meeting (AACR 2026) in San Diego. The open-label, multi-center study demonstrated encouraging anti-tumor activity with a 47.1% confirmed objective response rate (ORR) and 14.0-month median progression-free survival (PFS), validating Hansoh's strategic partnership with GSK following their exclusive global licensing agreement in December 2023.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63568#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63568"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63568#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharmaceutical Presents Promising Phase I Data for B7-H3 ADC Risvutatug Rezetecan Combined with Adebrelimab at AACR 2026 \u2013 47.1% ORR and 14.0-Month PFS in Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63568"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63568\/revisions"}],"predecessor-version":[{"id":63570,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63568\/revisions\/63570"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}